SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 9,838 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $79,982.94. Following the sale, the chief executive officer owned 660,391 shares in the company, valued at approximately $5,368,978.83. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, September 21st, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.33, for a total value of $3,515.26.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.23 during trading on Wednesday, reaching $7.15. 432,750 shares of the company’s stock were exchanged, compared to its average volume of 308,157. SOPHiA GENETICS SA has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The business has a 50 day moving average price of $7.82 and a 200 day moving average price of $6.12. The company has a market capitalization of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research increased their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright raised their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SOPH. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the first quarter worth about $50,000. Royal Bank of Canada boosted its holdings in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the last quarter. AXQ Capital LP acquired a new position in SOPHiA GENETICS during the second quarter valued at approximately $119,000. Silverberg Bernstein Capital Management LLC increased its stake in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS in the second quarter worth $567,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.